Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LYSO-7

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Neutrophils are the first line of defence during inflammatory processes; nevertheless, exacerbated influx and actions of… Expand
Is this relevant?
2016
2016
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor-γ (PPARγ) agonists used in treating type 2 diabetes that… Expand
Is this relevant?
2015
2015
We report the in vitro release profile and comparative pharmacokinetics and biodistribution of a new peroxisome proliferator… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor γ (PPARγ) agonists that improve insulin-mediated glucose… Expand
  • figure 1
  • figure 3
  • table 1
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Thiazolidinediones (TZD) are drugs used to treat type 2 diabetes mellitus as agents that enhance the insulin sensitivity. The… Expand
Is this relevant?
2013
2013
The compound (5Z)-5-[(5-bromo-1H-indol-3-yl)methylene]-3-(4-chlorobenzyl)-thiazolidine-2,4-dione (LYSO-7) was synthesised in… Expand
Is this relevant?
2013
2013
The present study aimed to show the in vivo mechanisms of action of an indole-thiazolidine molecule peroxisome-proliferator… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?